Antiangiogenic Therapy Combined with TACE – More Beneficial Therapeutic Effect in HCC

Z. Wang,z. Li

DOI: https://doi.org/10.1111/j.1365-2036.2010.04289.x

IF: 9.524

2010-01-01

Alimentary Pharmacology & Therapeutics

Abstract:Sirs, We have read with interest the article by Cabrera et al. on the management of hepatocellular carcinoma (HCC).1 We agree with the conclusions that studies combining targeted molecular therapies with locoregional therapies are likely to improve responses and outcome and a multidisciplinary approach is critical to the successful management of HCC.1 These conclusions have been verified by a new interest in antiangiogenic therapy combined with transcatheter arterial chemoembolization (TACE) in China. Hao et al. revealed that thalidomide, an antiangiogenic drug,2 combined with TACE achieved the primary study end-point in HCC.3 A controlled randomized trial was performed from August 2004 to August 2006; 96 HCC patients were randomized into combination group (thalidomide plus TACE, 45 cases) and TACE group (placebo plus TACE, 51 cases). Combination group received oral administration of thalidomide (200 mg/day) for 3–6 months and management of TACE three times. And TACE group received oral administration of placebo and management of TACE three times. Median overall survival was 28 months (95% CI, 12–24 months) in the combination group and 13 months (95% CI, 10–16 months) in the TACE group (P < 0.05). Moreover, as shown in the Figure 1, the 6-month, 1-year and 2-year survival rates were 97.0%, 75.3% and 51.0% respectively in combination group, and 84.8%, 54.9% and 24.6% respectively in TACE group.3 In addition, adverse events in TACE combined with thalidomide were mild and infrequent. Survival curves of the HCC patients in combination group (thalidomide plus TACE) and TACE group (placebo plus TACE). In combination group, HCC patients treated with thalidomide for 3–6 months. Adapted from Hao et al.3 In summary, compared with TACE alone, the combination of thalidomide and TACE can significantly inhibit progression of HCC and prolong survival of HCC patients. Thus, it is suggested that antiangiogenic therapy combined with TACE can significantly improve survival of HCC. And we consider that combining targeted molecular therapies with locoregional therapies, such as antiangiogenic therapy combined with TACE, may be potential and promising therapies for HCC. Declaration of personal and funding interests: None.